X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
JBI-802 is a first-in-class CoREST inhibitor with the dual activity on LSD1 and HDAC6. It is under phase 1/2 clinical development for the treatment of essential thrombocythemia & myeloproliferative neoplasms with thrombocytosis.
Lead Product(s): JBI-802
Therapeutic Area: Oncology Product Name: JBI-802
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Details:
JBI-589 is a PAD4 inhibitor which inhibits NET formation, in vitro resulting in reduced measures of RA and inflammation including joint erosion, RA clinical score and inflammatory markers.
Lead Product(s): JBI-589
Therapeutic Area: Immunology Product Name: JBI-589
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 13, 2023
Details:
JBI-778 is a potent and selective brain penetrant inhibitor of PRMT5, which is overexpressed in many cancers. JBI-778 is in development for the treatment of advance cancers with specific genetic mutations, and patients with high-grade glioma.
Lead Product(s): JBI-778
Therapeutic Area: Oncology Product Name: JBI-778
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2023
Details:
JBI-802 is an oral, potent and selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6. It targets stem cell modulation by inhibiting LSD1 and modulates immune suppression with isoform selective HDAC6 inhibition.
Lead Product(s): JBI-802
Therapeutic Area: Oncology Product Name: JBI-802
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
JBI-778, an oral, brain penetrant and selective protein arginine methyl transferase 5 (PRMT5) inhibitor, for the treatment of solid tumors with brain metastases and primary brain tumors including high-grade glioma.
Lead Product(s): JBI-778
Therapeutic Area: Oncology Product Name: JBI-778
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2022
Details:
JBI-2174, anti-PD-L1 candidate demonstrated strong affinity for PD-L1 with an IC50 of approximately 1 nM. In selectivity assays for immune-oncology targets, JBI-2174 was highly selective for PD-L1 also inhibited PD-L1/PD-1 mediated signaling essential for T-cell modulation.
Lead Product(s): JBI-2174
Therapeutic Area: Oncology Product Name: JBI-2174
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Details:
JBI-802 is a first-in-class, small-molecule, orally administered selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6, that has demonstrated synergistic anti-tumor activity in animal models.
Lead Product(s): JBI-802
Therapeutic Area: Oncology Product Name: JBI-802
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2022
Details:
JBI-1044, first-in-class PAD4 inhibitors with potential to be a next-generation treatment for an autoimmune disease with broad disease application including NETosis mediated tumor metastasis.
Lead Product(s): JBI-1044
Therapeutic Area: Oncology Product Name: JBI-1044
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2022
Details:
JBI-802, a novel dual LSD1 and HDAC6 Inhibitor received FDA Clearance of IND, on the basis of preclinical data that has demonstrated synergistic anti-tumor activity, and a favorable safety profile with no significant safety concerns or accumulation.
Lead Product(s): JBI-802
Therapeutic Area: Oncology Product Name: JBI-802
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2022
Details:
Collaboration aims to evaluate the ability of Peptidyl Arginine Deiminase 4 (PAD4) inhibitors provided by Jubilant Therapeutics to block neutrophil extracellular trap (NET) formation in the context of COVID-19 related cytokine storms.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: The Wistar Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 15, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
